Key Dosing Considerations With EXPAREL

INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK

USE 133 mg (10 mL) OF EXPAREL FOR INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK*

• Do not exceed maximum dosage of 133 mg (10 mL) of EXPAREL

ADMIXING WITH BUPIVACAINE HCl

10 mL EXPAREL (133 mg) + 15 mL Bupivacaine HCl 0.5% (up to 75 mg) = UP TO 25 mL TOTAL
10 mL EXPAREL (133 mg) + 30 mL Bupivacaine HCl 0.25% (up to 75 mg) = UP TO 40 mL TOTAL

FIELD BLOCK

USE 266 mg (20 mL) OF EXPAREL FOR FIELD BLOCKS, SUCH AS TAP AND PEC BLOCKS†

• Do not exceed maximum dosage of 266 mg (20 mL) of EXPAREL

VOLUME EXPANSION AND ADMIXING WITH BUPIVACAINE HCl

20 mL EXPAREL (266 mg) + 30 mL Bupivacaine HCl 0.5% (up to 150 mg) = UP TO 50 mL TOTAL
20 mL EXPAREL (266 mg) + 60 mL Bupivacaine HCl 0.25% (up to 150 mg) = UP TO 80 mL TOTAL

Key Dosing Considerations With EXPAREL

INDICATION

EXPAREL is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

IMPORTANT SAFETY INFORMATION

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the same site 20 minutes after injecting lidocaine.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, or intravascular or intra-articular use. The potential sensory and/or motor loss with nerve blocks other than interscalene brachial plexus nerve block, or intravascular or intra-articular use.

There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use.

Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use.

Please refer to full Prescribing Information. For more information, please visit www.EXPAREL.com or call 1-855-RX-EXPAREL (793-9727).